NeoPharm investors exact revenge on trial failure

NeoPharm was also dealing with the ugly aftermath of its own trial failure this morning. Its stock plunged more than 70 percent after the company announced that its experimental therapy for malignant tumors of the central nervous system had failed a Phase III trial, failing to prove more effective than an existing therapy. Officials will also ponder the fate of cintredekin besudotox with regulators and researchers.

"Top-line data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," said Guillermo Herrera, Neopharm's president and CEO. "We will continue to work with our Scientific Advisory Board and the FDA to determine the best path forward."

- see this press release on the trial
- here's the AP report on the data

Related Articles:
Analysts turn bullish on Neopharm's IL-13. Report
NeoPharm announces job cuts in restructuring. Report